Semaglutide, the active ingredient in Ozempic and Wegovy, primarily mimics GLP-1
12 In December 2025, high-dose oral semaglutide (Wegovy) became the first orally administered GLP-1 RA approved for obesity treatment, providing a noninjectable alternative within the IBT class
The degree of inflammation of the colon was graded semiquantitatively from 0 to 11 according to described criteria (Appleyard and Wallace, 1995) taking into consideration (1) loss of mucosal architecture (score 03), (2) cellular infiltration (score 03) (3) muscle thickening (score 03), (4) crypt abscess formation (score 01) and (5) goblet cell depletion (score 01)
Glucose metabolism under stress can quickly overwhelm and generate oxidative damage, whereas ketones are a cleaner-burning fuel that mitochondria can use more efficiently
GLP-1 activation alone produces meaningful weight loss, as demonstrated by Semaglutide achieving approximately 15% reduction in clinical trials
